Thanks to its response to the Covid-19 pandemic, the pharmaceutical industry has greatly improved its controversial image among patient advocacy groups, according to a new survey.
Specifically, 59% of patient groups thought brand-name drugmakers developed an “excellent” or “good” reputation last year, up from 50% in 2020. This was also the best showing since the survey was started in 2011 by PatientView, a research firm that canvassed 2,150 patient groups from 89 countries between November 2021 and February 2022. The firm rated the reputations of 47 companies.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
